National Cancer Centre, Singapore

This study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (stomach cancer, liver cancer, or other types) that had stopped responding to standard treatments. The drug was given by IV every two weeks for up to 12 doses, with the option to continue if pa…

This study tested a 6-month program called ENABLE for heart failure patients and their caregivers in Singapore. The program provides education, support, and advice to improve quality of life. Researchers enrolled 125 participants to see if the program was feasible and acceptable.…

This study looked at over 1000 patients who had surgery for liver cancer (HCC) to better predict how long they might live after the operation. Researchers used a 'metro ticket' approach that considers tumor size, number of tumors, and a blood marker called AFP. The goal is to hel…

This study looked at how the immune drug pembrolizumab affects colorectal cancer when given before surgery. 33 patients with non-metastatic cancer received the drug along with chemotherapy or chemoradiotherapy. The goal was to measure changes in immune activity and tumor shrinkag…

This early-phase study tested whether the drug bexarotene can change the behavior of triple-negative breast cancer cells that have stopped responding to taxane chemotherapy. The goal was to see if this change could make the cancer sensitive to chemotherapy again. Twelve women wit…

This study looked at what happens when healthy adults eat durian every day for two weeks. Researchers measured changes in gut bacteria, blood sugar, and cholesterol levels. The goal was to learn how this fruit affects the body's microbiome and metabolism.

This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) that had stopped responding to targeted treatments. The goal was to find genetic changes in the blood that explain why the drugs stopped working. By matching these changes to the …